IMPACT THERAP-B (07630) made its debut on the stock exchange. According to the announcement, the shares were priced at HKD 20.1 each, with a total of 41.977 million shares issued. Each board lot consists of 200 shares, and the net proceeds from the offering amount to approximately HKD 760 million. As of the latest update, the stock has risen by 76.62% to HKD 35.5, with a turnover of HKD 207 million.

Public information indicates that IMPACT THERAP-B is a commercial-stage biotechnology company dedicated to advancing precision anti-cancer therapies based on synthetic lethality mechanisms globally. The company focuses on developing innovative treatments to address unmet medical needs for cancer patients. Its core product, Senaparib, officially commenced commercialization after receiving approval in January 2025 for first-line maintenance therapy in ovarian cancer for the "entire population" in China.

As of the latest practicable date, IMPACT THERAP-B has established a pipeline of one commercialized product, four clinical-stage products, and seven preclinical products. This pipeline covers small molecule inhibitors targeting key synthetic lethality targets, including PARP1/2, PARP1, ATR, WEE1, and PKMYT1/WEE1. The company is also exploring emerging therapies such as ADC and protein degrader candidates. It is one of only three companies globally with both a commercial-stage PARP1/2 inhibitor and a clinical-stage next-generation PARP1-selective inhibitor.